La atropina superdiluida al 0,01% frena el aumento de miopía en niños-adolescentes.Un estudio a largo plazo 5 años de evolución: seguridad y eficacia.
- 1 Universidad de Valencia, Valencia, España
ISSN: 0365-6691
Año de publicación: 2018
Volumen: 93
Número: 4
Páginas: 182-185
Tipo: Artículo
Otras publicaciones en: Archivos de la Sociedad Española de Oftalmologia
Objetivos de desarrollo sostenible
Resumen
Objective To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. Material and methods A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed. Results Myopia progression of the treated group was −0.14±0.35 versus −0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. Conclusion Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.